0HD2 Stock Chart & Stats
$235.93
-$0.72(-0.25%)
At close: 4:00 PM EDT
$235.93
-$0.72(-0.25%)
Day’s Range― - ―
52-Week Range$199.81 - $500.21
Previous CloseN/A
Volume443.00
Average Volume (3M)720.00
Market Cap
$32.03B
Enterprise Value$41.31K
Total Cash (Recent Filing)$3.31B
Total Debt (Recent Filing)$1.27B
Price to Earnings (P/E)40.2
Beta0.57
Next Earnings
Oct 29, 2026EPS Estimate
1.78Next Dividend Ex-DateN/A
Dividend Yield0.28%
Share Statistics
EPS (TTM)6.10
Shares Outstanding133,809,110
10 Day Avg. Volume518
30 Day Avg. Volume720
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)66.01
Price to Sales (P/S)14.03
P/FCF Ratio111.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$377.31Price Target Upside59.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)6.72
Revenue Forecast (FY)$5.47B
Bulls Say, Bears Say
Bulls Say
Rapid Product Revenue GrowthStrong product revenue growth demonstrates substantial demand for Alnylam’s commercial portfolio and expanding adoption of its RNAi medicines. Continued uptake can strengthen operating leverage, support reinvestment in the pipeline, and reinforce the company’s position in TTR therapeutics over the next several quarters.
Profitability And Cash GenerationThe shift to meaningful profitability alongside strong operating and free cash flow improves Alnylam’s ability to fund clinical development internally. Healthy cash conversion supports financial resilience, lowers reliance on external capital, and provides flexibility to advance products and partnerships through the development cycle.
Commercial Adoption And Prescriber ExpansionBroadening prescriber adoption and high reported adherence indicate that AMVUTTRA is gaining durable use in clinical practice rather than relying only on initial launch demand. A larger prescriber base and persistent treatment can support recurring revenue growth and deepen the franchise’s market position.
Bears Say
TTR Guidance ReductionThe guidance reduction shows that early launch demand was stronger than the sustainable near-term run rate, creating execution risk around growth expectations. Although the revised outlook still implies substantial expansion, normalization may make future revenue progression less linear and increase dependence on new patient starts.
Royalty-driven Margin PressureHigher royalty rates on a rapidly growing product directly reduce the economic benefit of additional sales and can limit operating leverage. If royalty intensity remains elevated as AMVUTTRA scales, Alnylam may need continued revenue growth and cost discipline to preserve margin expansion and earnings quality.
History Of Losses And Earnings VolatilityThe recent turnaround is significant, but prior losses and uneven revenue growth indicate that Alnylam’s earnings run rate has not yet been proven across cycles. Sustained profitability will depend on maintaining product momentum while funding costly clinical programs and avoiding renewed operating cost escalation.
Alnylam Pharma News
0HD2 FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest share price was $199.81 and its highest was $500.21 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $32.03B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Oct 29, 2026 which is in 41 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Jul 30, 2026. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.63 by -$0.42.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 0.28%. See more information on Alnylam Pharmaceuticals dividends here
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is 1.78.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 133,809,110 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of $1.21 in its last earnings report, missing expectations of $1.63. Following the earnings report the stock price went down -29.085%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0HD2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alnylam Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$377.31 (59.92% Upside)
$377.31 (59.92% Upside)
Blogger Sentiment
Bullish
GB:0HD2 Sentiment 69%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
0HD2 Company Deck
0HD2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum — highlighted by record quarterly AMVUTTRA and broad TTR revenue growth, expanding prescriber base, robust cash and operating income, strategic geographic and AI partnerships, and an active pipeline with upcoming data readouts. Negative elements included a $200M downward revision to 2026 TTR guidance tied to normalization of early switch demand, a Q2 decline in collaboration revenue, margin pressure from higher royalties, increased R&D/SG&A investment, and industry uncertainty following a competitor trial failure (CARDIO-TTRansform). Management framed the guidance reduction as a learning from early launch dynamics and emphasized confidence in long-term TTR leadership and nucresiran’s prospects, indicating highlights outweigh challenges.View all GB:0HD2 earnings summaries0HD2 Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
0HD2 Stock 12 Month Forecast
Average Price Target
$377.31
▲(59.92% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―